

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Theresa L. O'Keefe

Application No.: 10/718,495 Group Art Unit: 1644

Filed: November 20, 2003 Examiner: Maher M. Huddad Ph.D.

Confirmation No.: 9229

USE OF HMGB FRAGMENTS AS ANTI-INFLAMMATORY AGENTS

CERTIFICATE OF MAILING OR TRANSMISSION

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, or is being facsimile transmitted to the United States Patent and Trademark Office on:

MAY 14, 2006

Date

Christine A. Budd

Signature

CHRISTINE A. BUDD

Typed or printed name of person signing certificate

INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

05/19/2006. FFANAEIA 00000097 10718495

Sir:

01 FC:1806 180.00 OP

This Information Disclosure Statement is submitted:

under 37 CFR 1.129(a), or  
(First/Second submission after Final Rejection)

under 37 CFR 1.97(b), or

(Within any one of the following time periods: three months of filing national application (other than a CPA) or date of entry of the national stage in an international application; or before the mailing date of a first office action on the merits in a non-provisional application, including a CPA, or a Request for Continued Examination).

under 37 CFR 1.97(c) together with either:

a Statement under 37 CFR 1.97(e), as checked below, or

a \$180.00 fee under 37 CFR 1.17(p), or

(After the 37 CFR 1.97(b) time period, but before final action or notice of allowance, whichever occurs first)

under 37 CFR 1.97(d) together with:

a Statement under 37 CFR 1.97(e), as checked below, and

a \$180.00 fee under 37 CFR 1.17(p), or

(Filed after final action or notice of allowance, whichever occurs first, but on or before payment of the issue fee)

under 37 CFR 1.97(i):

Applicant requests that the IDS and cited reference(s) be placed in the application filewrapper.

(Filed after payment of issue fee)

Statement Under 37 CFR 1.97(e)

- Each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement; or
- No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned, after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

Statement Under 37 CFR 1.704(d) (Patent Term Adjustment)

Applies to original applications (other than design) filed on or after May 29, 2000

- Each item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart application and this communication was not received by any individual designated in § 1.56(c) more than thirty days prior to the filing of the Information Disclosure Statement.

Enclosed herewith is form PTO-1449:

- Copies of the cited references B1-B9 and C1-C67 are enclosed.
  - Copies of issued U.S. patents and published U.S. applications are not required and are not being provided.
  - Copies of the cited references are enclosed except those entered in prior application, U.S. Application No. [ ], to which priority under 35 U.S.C. 120 is claimed. [The earlier application contains copies of the cited references.]
- The listed references (C2, C3 and C48) were cited in the enclosed International Search Report in a counterpart foreign application.
- The "concise explanation" requirement (non-English references) for reference B8 under 37 CFR 1.98(a)(3) is satisfied by:
  - the explanation provided on the attached sheet.
  - the explanation provided in the Specification.
  - submission of the enclosed International Search Report.
  - submission of the enclosed English-language version of a foreign Search Report and/or foreign Office Action.
- the enclosed English language abstract.

[ ] Applicant requests that the following non-published pending applications be considered:  
*(Affix a label or apply the stamp "Non-Published IDS Reference - Do Not Scan" to the front of each unpublished pending appl'n.)*

Examiner's  
Initials

\_\_\_\_ U.S. Patent Application No. [ ], by [inventor(s)], filed [ ], Docket No.: [ ]  
 \_\_\_\_ U.S. Patent Application No. [ ], by [inventor(s)], filed [ ], Docket No.: [ ]  
 \_\_\_\_ U.S. Patent Application No. [ ], by [inventor(s)], filed [ ], Docket No.: [ ]

\_\_\_\_ Examiner

\_\_\_\_ Date

[ ] A copy of each above-cited applications, including the current claims, is enclosed.  
 [ ] A copy of each above-cited application, including the current claims, is enclosed, except those entered in prior application, U.S. Application No. [ ], to which priority under 35 U.S.C. 120 is claimed.

The Examiner is requested to return a copy of the above list of pending applications indicating which references were considered with the next office communication.

It is requested that the information disclosed herein be made of record in this application.

Method of payment:

[X] A check for the fee noted above is enclosed, or the fee has been included in the check with the accompanying Reply. A copy of this Statement is enclosed.  
 [ ] Please charge Deposit Account 08-0380 in the amount of \$[ ]. A copy of this Statement is enclosed.  
 [X] Please charge any deficiency in fees and credit any overpayment to Deposit Account 08-0380.

Respectfully submitted,

HAMILTON, BROOK, SMITH & REYNOLDS, P.C.

By Kristin Connarn  
 Kristin A. Connarn  
 Registration No.: 57,025  
 Telephone: (978) 341-0036  
 Facsimile: (978) 341-0136

Concord, MA 01742-9133

Dated: May 16, 2006

PTO-1449 REPRODUCED <b>O I P E</b> INFORMATION DISCLOSURE CITATION IN AN APPLICATION May 16, 2006 (Use several sheets if necessary)		ATTORNEY DOCKET NO. 3258.1009-001	APPLICATION NO. 10/718,495
		FIRST NAMED INVENTOR Theresa L. O'Keefe	FILING DATE 11/20/2003
		EXAMINER Maher M. Huddad Ph.D.	CONFIRMATION NO. 9229
			GROUP 1644

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL	REF. NO.	DOCUMENT NUMBER Number-Kind Code (if known)	ISSUE DATE / PUBLICATION DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT
	A1	5,594,114	01/14/1997	Goodearl, A. D. J., <i>et al.</i>
	A2	6,303,321 B1	10/16/2001	Tracey, K. J. and Wang, H.
	A3	6,448,223 B1	09/10/2002	Tracey, K. J. and Wang, H.
	A4	6,468,533 B1	10/22/2002	Tracey, K. J. and Wang, H.
	A5	2003/0060410 A1	03/27/2003	Tracey, K. J., <i>et al.</i>
	A6	2003/0144201 A1	07/31/2003	Tracey, K. J., <i>et al.</i>
	A7	2004/0005316 A1	01/08/2004	Tracey, K. J. and Yang, H.
	A8	2004/0053841 A1	03/18/2004	Tracey, K. J. and Yang, H.
	A9	6,171,779 B1	01/09/2001	Chada, K.K., <i>et al.</i>
	A10	6,720,472 B2	04/13/2004	Chada, K.K., <i>et al.</i>
	A11	2002/0009749 A1	01/24/2002	Ozaki, S., <i>et al.</i>
	A12	6,323,329 B1	11/27/2001	Bullerdiek, J.
	A13	US 6,677,321 B1	01/13/2004	Levin, B.
	A14			
	A15			
	A16			
	A17			
	A18			
	A19			
	A20			
	A21			
	A22			
	A23			
	A24			
	A25			

EXAMINER	DATE CONSIDERED
----------	-----------------

PTO-1449 REPRODUCED  <b>INFORMATION DISCLOSURE CITATION IN AN APPLICATION</b>  May 16, 2006  (Use several sheets if necessary)		ATTORNEY DOCKET NO. 3258.1009-001	APPLICATION NO. 10/718,495
		FIRST NAMED INVENTOR Theresa L. O'Keefe	FILING DATE 11/20/2003
		EXAMINER Maher M. Huddad Ph.D.	CONFIRMATION NO. 9229
			GROUP 1644

FOREIGN PATENT DOCUMENTS					
		DOCUMENT NUMBER Country Code-Number-Kind Code (if known)	DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT	TRANSLATION YES NO
B1		WO 00/47104 A2	08/17/2000	The Picower Institute for Medical Research	
B2		WO 99/59609 A2	11/25/1999	Bartorelli, A.	
B3		WO 02/074337 A1	09/26/2002	Bianchi, M. E., <i>et al.</i>	
B4		WO 2004/004763 A2	01/15/2004	Bianchi, M. E., <i>et al.</i>	
B5		JP 62-166897	07/23/1987	Toyo Soda Mfg. Co., Ltd.	X
B6		EP 1 079 849 B1	01/02/2002	Bartorelli, A.	
B7		WO 96/25493 A1	08/22/1996	Bullerdiek, J.	
B8		WO 97/23611 A2	07/03/1997	Bullerdiek, J.	X
B9		WO 99/59609 A2	11/25/1999	Bartorelli, A.	
B10					
B11					
B12					
B13					
B14					
B15					
B16					
B17					
B18					
B19					
B20					
B21					
B22					
B23					
B24					

EXAMINER	DATE CONSIDERED
----------	-----------------

PTO-1449 REPRODUCED		ATTORNEY DOCKET NO. 3258.1009-001	APPLICATION NO. 10/718,495	
INFORMATION DISCLOSURE CITATION IN AN APPLICATION		FIRST NAMED INVENTOR Theresa L. O'Keefe		FILING DATE 11/20/2003
May 16, 2006  (Use several sheets if necessary)		EXAMINER Maher M. Huddad Ph.D.	CONFIRMATION NO. 9229	GROUP 1644

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)				
C1	Abaza, M.-S. I. and Atassi, M. Z., "Effects of Amino Acid Substitutions Outside an Antigenic Site on Protein Binding to Monoclonal Antibodies of Predetermined Specificity Obtained by Peptide Immunization: Demonstration with Region 94-100 (Antigenic Site 3) of Myoglobin," <i>J. Protein Chem.</i> , 11(5):433-444 (1992).			
C2	Abraham, E., <i>et al.</i> , "Cutting Edge: HMG-1 as a Mediator of Acute Lung Inflammation," <i>J. Immunol.</i> , 165:2950-2954 (2000).			
C3	Andersson, U., <i>et al.</i> , "High Mobility Group 1 Protein (HMG-1) Stimulates Proinflammatory Cytokine Synthesis in Human Monocytes," <i>J. Exp. Med.</i> , 192(4):565-570 (2000).			
C4	Ayer, L. M., <i>et al.</i> , "Antibodies to HMG Proteins in Patients With Drug-Induced Autoimmunity," <i>Arthritis Rheum.</i> , 37(1):98-103 (1994).			
C5	Banks, G. C., <i>et al.</i> , "The HMG-I(Y) A-T-hook Peptide Motif Confers DNA-binding Specificity to a Structured Chimeric Protein," <i>J. Biol. Chem.</i> , 274(23):16536-16544 (1999).			
C6	Baxevanis, A. D. and Landsman, D., "The HMG-1 Box Protein Family: Classification and Functional Relationships," <i>Nucleic Acids Res.</i> , 23(9):1604-1613 (1995).			
C7	Bianchi, M. E., <i>et al.</i> , "The DNA Binding Site of HMG1 Protein is Composed of Two Similar Segments (HMG Boxes), Both of Which Have Counterparts in Other Eukaryotic Regulatory Proteins," <i>EMBO J.</i> , 11(3):1055-1063 (1992).			
C8	Bianchi, M. E., <i>et al.</i> , "Specific Recognition of Cruciform DNA by Nuclear Protein HMG1," <i>Science</i> , 243:1056-1059 (1989).			
C9	Bustin, M., "Revised Nomenclature for High Mobility Group (HMG) Chromosomal Proteins," <i>Trends Biochem. Sci.</i> , 26:152-153 (2001).			
C10	Bustin, M., <i>et al.</i> , "Antigenic Determinants of High Mobility Group Chromosomal Proteins 1 and 2," <i>Biochem.</i> , 21:6773-6777 (1982).			
C11	Bustin, M., <i>et al.</i> , "Immunological Relatedness of High Mobility Group Chromosomal Proteins from Calf Thymus," <i>J. Biol. Chem.</i> , 253(5):1694-1699 (1978).			

EXAMINER	DATE CONSIDERED
----------	-----------------

PTO-1449 REPRODUCED  <b>INFORMATION DISCLOSURE CITATION IN AN APPLICATION</b>  May 16, 2006  (Use several sheets if necessary)		ATTORNEY DOCKET NO. 3258.1009-001	APPLICATION NO. 10/718,495
		FIRST NAMED INVENTOR Theresa L. O'Keefe	FILING DATE 11/20/2003
		EXAMINER Maher M. Huddad Ph.D.	CONFIRMATION NO. 9229
			GROUP 1644

OTHER DOCUMENTS ( <i>Including Author, Title, Date, Pertinent Pages, Etc.</i> )		
C12	Chou, D. K. H., <i>et al.</i> , "Identity of Nuclear High-Mobility-Group Protein, HMG-1, and Sulfoglucuronyl Carbohydrate-Binding Protein, SBP-1, in Brain," <i>J. Neurochem.</i> , 77:120-131 (2001).	
C13	Colman, P. M., "Effects of Amino Acid Sequence Changes on Antibody-Antigen Interactions," <i>Res. Immunol.</i> , 145(1):33-36 (1994).	
C14	Czura, C., <i>et al.</i> , "Dual Roles for HMGB1: DNA Binding and Cytokine," <i>J. Endotoxin Res.</i> , 7(4):315-321 (2001).	
C15	Daston, M. M. and Ratner, N., "Expression of P30, a Protein with Adhesive Properties in Schwann Cells and Neurons of the Developing and Regenerating Peripheral Nerve," <i>J. Cell Biol.</i> , 112(6):1229-1239 (1991).	
C16	Degryse, B., <i>et al.</i> , "The High Mobility Group (HMG) Boxes of the Nuclear Protein HMG1 Induce Chemotaxis and Cytoskeleton Reorganization in Rat Smooth Muscle Cells," <i>J. Cell Biol.</i> , 152(6):1197-1206 (2001).	
C17	Falciola, L., <i>et al.</i> , "High Mobility Group 1 Protein is Not Stably Associated with the Chromosomes of Somatic Cells," <i>J. Cell. Biol.</i> , 137(1):19-26 (1997).	
C18	Freeman, B. D., <i>et al.</i> , "The Role of Inflammation in Sepsis and Septic Shock: A Meta-Analysis of Both Clinical and Preclinical Trials of Anti-Inflammatory Therapies," in <i>Inflammation: Basic Principles and Clinical Correlates</i> , John I. Gallin and Ralph Snyderman eds. (Lippincott, Williams & Wilkins, Philadelphia), pp 965-975 (1999).	
C19	Imamura, T., <i>et al.</i> , "Interaction with p53 Enhances Binding of Cisplatin-Modified DNA by High Mobility Group 1 Protein," <i>J. Biol. Chem.</i> , 276(10):7534-7540 (2001).	
C20	Ise, T., <i>et al.</i> , "Transcription Factor Y-Box Binding Protein 1 Binds Preferentially to Cisplatin-Modified DNA and Interacts With Proliferating Cell Nuclear Antigen," <i>Cancer Res.</i> , 59:342-346 (1999).	
C21	Johns, E. W., <i>et al.</i> , "History, Definitions and Problems," in <i>The HMG Chromosomal Proteins</i> , Johns, E.W., ed. (London: Academic Press), pp. 1-7 (1982).	

EXAMINER	DATE CONSIDERED
----------	-----------------

PTO-1449 REPRODUCED  <b>INFORMATION DISCLOSURE CITATION IN AN APPLICATION</b>  May 16, 2006  (Use several sheets if necessary)		ATTORNEY DOCKET NO. 3258.1009-001	APPLICATION NO. 10/718,495
		FIRST NAMED INVENTOR Theresa L. O'Keefe	FILING DATE 11/20/2003
		EXAMINER Maher M. Huddad Ph.D.	CONFIRMATION NO. 9229
			GROUP 1644

OTHER DOCUMENTS ( <i>Including Author, Title, Date, Pertinent Pages, Etc.</i> )			
C22	Jung, F., <i>et al.</i> , "Antibodies Against a Peptide Sequence Located in the Linker Region of the HMG-1/2 Box Domains in Sera From Patients With Juvenile Rheumatoid Arthritis," <i>Arthritis Rheum.</i> , 40(10):1803-1809 (1997).		
C23	Landsman, D. and Bustin, M., "A Signature for the HMG-1 Box DNA-Binding Proteins," <i>BioEssays</i> , 15(8):539-546 (1993).		
C24	Lederman, S., <i>et al.</i> , "A Single Amino Acid Substitution in a Common African Allele of the CD4 Molecule Ablates Binding of the Monoclonal Antibody OKT4," <i>Mol. Immunol.</i> , 28(11):1171-1181 (1991).		
C25	Ma, W., <i>et al.</i> , "Detection of Anti-neutrophil Cytoplasmic Antibodies in MRL/Mp- <i>lpr/lpr</i> Mice and Analysis of Their Target Antigens," <i>Autoimmunity</i> , 32(4):281-291 (2000).		
C26	Melloni, E., <i>et al.</i> , "Identity in Molecular Structure Between 'Differentiation Enhancing Factor' of Murine Erythroleukemia Cells and the 30 kD Heparin-Binding Protein of Developing Rat Brain," <i>Biochem. Biophys. Res. Commun.</i> , 210(1):82-89 (1995).		
C27	Melloni, E., <i>et al.</i> , "Extracellular Release of the 'Differentiation Enhancing Factor', a HMG1 Protein Type, is an Early Step in Murine Erythroleukemia Cell Differentiation," <i>FEBS Lett.</i> , 368:466-470 (1995).		
C28	Merenmies, J., <i>et al.</i> , "30-kDa Heparin-Binding Protein of Brain (Amphoterin) Involved in Neurite Outgrowth," <i>J. Biol. Chem.</i> , 266(25):16722-16729 (1991).		
C29	Milev, P., <i>et al.</i> , "High Affinity Binding and Overlapping Localization of Neurocan and Phosphacan/Protein-Tyrosine Phosphatase - $\zeta/\beta$ with Tenascin-R, Amphoterin, and the Heparin-Binding Growth-Associated Molecule," <i>J. Biol. Chem.</i> 273(12):6998-7005 (1998).		
C30	Mohan, P. S., <i>et al.</i> , "Sulfoglycolipids Bind to Adhesive Protein Amphoterin (p30) in the Nervous System," <i>Biochem. Biophys. Res. Commun.</i> , 182(2):689-696 (1992).		
C31	Parkkinen, J. and Rauvala, H., "Interactions of Plasminogen and Tissue Plasminogen Activator (t-PA) with Amphoterin," <i>J. Biol. Chem.</i> , 266(25):16730-16735 (1991).		
C32	Parkkinen, J., <i>et al.</i> , "Amphoterin, the 30-kDa Protein in a Family of HMG1-type Polypeptides," <i>J. Biol. Chem.</i> , 268(26):19726-19738 (1993).		

EXAMINER	DATE CONSIDERED
----------	-----------------

PTO-1449 REPRODUCED  <b>INFORMATION DISCLOSURE CITATION IN AN APPLICATION</b>  May 16, 2006  (Use several sheets if necessary)		ATTORNEY DOCKET NO. 3258.1009-001	APPLICATION NO. 10/718,495
		FIRST NAMED INVENTOR Theresa L. O'Keefe	FILING DATE 11/20/2003
		EXAMINER Maher M. Huddad Ph.D.	CONFIRMATION NO. 9229
			GROUP 1644

OTHER DOCUMENTS ( <i>Including Author, Title, Date, Pertinent Pages, Etc.</i> )			
C33	Passalacqua, M., <i>et al.</i> , "Stimulated Astrocytes Release High-Mobility Group 1 Protein, an Inducer of Lan-5 Neuroblastoma Cell Differentiation," <i>Neuroscience</i> , 82(4):1021-1028 (1998).		
C34	Rauvala, H. and Pihlaskari, R., "Isolation and Some Characteristics of an Adhesive Factor of Brain That Enhances Neurite Outgrowth in Central Neurons," <i>J. Biol. Chem.</i> , 262(34):16625-16635 (1987).		
C35	Rauvala, H., <i>et al.</i> , "The Adhesive and Neurite-Promoting Molecule p30: Analysis of the Amino-Terminal Sequence and Production of Antipeptide Antibodies That Detect p30 at the Surface of Neuroblastoma Cells and of Brain Neurons," <i>J. Cell Biol.</i> , 107(6):2293-2305 (1988).		
C36	Romani, M., <i>et al.</i> , "Serological Analysis of Species Specificity in the High Mobility Group Chromosomal Proteins," <i>J. Biol. Chem.</i> , 254(8):2918-2922 (1979).		
C37	Salmivirta, M., <i>et al.</i> , "Neurite Growth-Promoting Protein (Amphoterin, p30) Binds Syndecan," <i>Exp. Cell Res.</i> , 200:444-451 (1992).		
C38	Scaffidi, P., <i>et al.</i> , "Release of Chromatin Protein HMGB1 by Necrotic Cells Triggers Inflammation," <i>Nature</i> , 418:191-195 (2002).		
C39	Sobajima, J., <i>et al.</i> , "Prevalence and Characterization of Perinuclear Anti-Neutrophil Cytoplasmic Antibodies (P-ANCA) Directed Against HMG1 and HMG2 in Ulcerative Colitis (UC)," <i>Clin. Exp. Immunol.</i> , 111:402-407 (1998).		
C40	Sobajima, J., <i>et al.</i> , "Anti-Neutrophil Cytoplasmic Antibodies (ANCA) in Ulcerative Colitis: Anti-Cathepsin G and a Novel Antibody Correlate With a Refractory Type," <i>Clin. Exp. Immunol.</i> , 105:120-124 (1996).		
C41	Sobajima, J., <i>et al.</i> , "Novel Autoantigens of Perinuclear Anti-Neutrophil Cytoplasmic Antibodies (P-ANCA) in Ulcerative Colitis: Non-Histone Chromosomal Proteins, HMG1 and HMG2," <i>Clin. Exp. Immunol.</i> , 107:135-140 (1997).		
C42	Sobajima, J., <i>et al.</i> , "High Mobility Group (HMG) Non-Histone Chromosomal Proteins HMG1 and HMG2 are Significant Target Antigens of Perinuclear Anti-Neutrophil Cytoplasmic Antibodies in Autoimmune Hepatitis," <i>Gut</i> , 44:867-873 (1999).		

EXAMINER	DATE CONSIDERED
----------	-----------------

PTO-1449 REPRODUCED  <b>INFORMATION DISCLOSURE CITATION IN AN APPLICATION</b>  May 16, 2006  (Use several sheets if necessary)		ATTORNEY DOCKET NO. 3258.1009-001	APPLICATION NO. 10/718,495
		FIRST NAMED INVENTOR Theresa L. O'Keefe	FILING DATE 11/20/2003
		EXAMINER Maher M. Huddad Ph.D.	CONFIRMATION NO. 9229
			GROUP 1644

OTHER DOCUMENTS ( <i>Including Author, Title, Date, Pertinent Pages, Etc.</i> )			
C43	Sparatore, B. <i>et al.</i> , "Extracellular High-Mobility Group 1 Protein is Essential for Murine Erythroleukaemia Cell Differentiation," <i>Biochem. J.</i> , 320:253-256 (1996).		
C44	Suda, T., <i>et al.</i> , "A Novel Activity of HMG Domains: Promotion of the Triple-Stranded Complex Formation Between DNA Containing (GGA/TCC) <sub>11</sub> and d(GGA) <sub>11</sub> Oligonucleotides," <i>Nucleic Acids Res.</i> , 24(23):4733-4740 (1996).		
C45	Tsuneoka, M., <i>et al.</i> , "Monoclonal Antibody Against Non-Histone Chromosomal Protein High Mobility Group 1 Co-Migrates With High Mobility Group 1 Into the Nucleus," <i>J. Biol. Chem.</i> , 261(4):1829-1834 (1986).		
C46	Uesugi, H., <i>et al.</i> , "Prevalence and Characterization of Novel pANCA, Antibodies to the High Mobility Group Non-Histone Chromosomal Proteins HMG1 and HMG2, in Systemic Rheumatic Diseases," <i>J. Rheumatol.</i> , 25(4):703-709 (1998).		
C47	Vanderbilt, J. N. and Anderson, J. N., "Monoclonal Antibodies as Probes for the Complexity, Phylogeny, and Chromatin Distribution of High Mobility Group Chromosomal Proteins 1 and 2," <i>J. Biol. Chem.</i> , 260(16):9336-9345 (1985).		
C48	Wang, H., <i>et al.</i> , "HMG-1 as a Late Mediator of Endotoxin Lethality in Mice," <i>Science</i> , 285:248-251 (1999).		
C49	Wang, H., <i>et al.</i> , "Proinflammatory Cytokines (Tumor Necrosis Factor and Interleukin 1) Stimulate Release of High Mobility Group Protein-1 by Pituicytes," <i>Surgery</i> , 126(2):389-392 (1999).		
C50	Wen, L., <i>et al.</i> , "A Human Placental cDNA Clone that Encodes Nonhistone Chromosomal Protein HMG-1," <i>Nucleic Acids Res.</i> , 17(3):1197-1213 (1989).		
C51	Yamada, S., <i>et al.</i> , "High Mobility Group Protein 1 (HMGB1) Quantified by ELISA with a Monoclonal Antibody That Does Not Cross-React with HMGB2," <i>Clin. Chem.</i> , 49(9):1535-1537 (2003).		
C52	Zhang, M. and Tracey, K. J., "Tumor Necrosis Factor," in <i>The Cytokine Handbook</i> , 3 <sup>rd</sup> Ed., (Academic Press Limited), pp. 517-547 (1998).		

EXAMINER	DATE CONSIDERED
----------	-----------------

PTO-1449 REPRODUCED  <b>INFORMATION DISCLOSURE CITATION IN AN APPLICATION</b>  May 16, 2006  (Use several sheets if necessary)		ATTORNEY DOCKET NO. 3258.1009-001	APPLICATION NO. 10/718,495
		FIRST NAMED INVENTOR Theresa L. O'Keefe	FILING DATE 11/20/2003
		EXAMINER Maher M. Huddad Ph.D.	CONFIRMATION NO. 9229
			GROUP 1644

OTHER DOCUMENTS ( <i>Including Author, Title, Date, Pertinent Pages, Etc.</i> )			
C53	GenBank Accession No. AC010149, "Homo sapiens BAC clone RP11-395A23 from 2, complete sequence," (2001) [online] [retrieved on 11/7/2002]. Retrieved from the Internet: <URL: <a href="http://www.ncbi.nlm.nih.gov">http://www.ncbi.nlm.nih.gov</a> >.		
C54	GenBank Accession No. AF165167, "Homo sapiens high mobility group 1-like protein L8 (HMG1L8) retropseudogene, complete sequence," (2001) [online] [retrieved on 11/7/2002]. Retrieved from the Internet: <URL: <a href="http://www.ncbi.nlm.nih.gov">http://www.ncbi.nlm.nih.gov</a> >.		
C55	GenBank Accession No. AF076674, "Homo sapiens high mobility group 1-like protein L1 (HMG1L1) retropseudogene sequence," (1999) [online] [retrieved on 11/7/2002]. Retrieved from the Internet: <URL: <a href="http://www.ncbi.nlm.nih.gov">http://www.ncbi.nlm.nih.gov</a> >.		
C56	GenBank Accession No. AF076676, "Homo sapiens high mobility group 1-like protein L4 (HMG1L4) retropseudogene sequence," (1999) [online] [retrieved on 11/7/2002]. Retrieved from the Internet: <URL: <a href="http://www.ncbi.nlm.nih.gov">http://www.ncbi.nlm.nih.gov</a> >.		
C57	GenBank Accession No. NG_000897, "Homo sapiens high-mobility group (nonhistone chromosomal) protein 1-like 10 (HMG1L10) pseudogene on chromosome 22," (2002) [online] [retrieved on 11/7/2002]. Retrieved from the Internet: <URL: <a href="http://www.ncbi.nlm.nih.gov">http://www.ncbi.nlm.nih.gov</a> >.		
C58	GenBank Accession No. U51677, "Human non-histone chromatin protein HMG1 (HMG1) gene, complete cds.," (1996) [online] [retrieved on 11/12/2004]. Retrieved from the Internet: <URL: <a href="http://www.ncbi.nlm.nih.gov">http://www.ncbi.nlm.nih.gov</a> >.		
C59	GenBank Accession No. XM_066789, "Homo sapiens similar to high mobility group 1 (LOC139603), mRNA," (2002) [online] [retrieved on 11/7/2002]. Retrieved from the Internet: <URL: <a href="http://www.ncbi.nlm.nih.gov">http://www.ncbi.nlm.nih.gov</a> >.		
C60	GenBank Accession No. AF165168, "Homo sapiens high mobility group 1-like protein L9 (HMG1L9) retropseudogene sequence, complete sequence," (2001) [online] [retrieved on 11/7/2002]. Retrieved from the Internet: <URL: <a href="http://www.ncbi.nlm.nih.gov">http://www.ncbi.nlm.nih.gov</a> >.		
C61	GenBank Accession No. XM_063129, "Homo sapiens similar to high mobility group 1 (LOC122441), mRNA," (2002) [online] [retrieved on 11/12/2004]. Retrieved from the Internet: <URL: <a href="http://www.ncbi.nlm.nih.gov">http://www.ncbi.nlm.nih.gov</a> >.		

EXAMINER	DATE CONSIDERED
----------	-----------------

PTO-1449 REPRODUCED  <b>INFORMATION DISCLOSURE CITATION IN AN APPLICATION</b>  May 16, 2006  (Use several sheets if necessary)	ATTORNEY DOCKET NO. 3258.1009-001	APPLICATION NO. 10/718,495
	FIRST NAMED INVENTOR Theresa L. O'Keefe	FILING DATE 11/20/2003
	EXAMINER Maher M. Huddad Ph.D.	CONFIRMATION NO. 9229
		GROUP 1644

OTHER DOCUMENTS ( <i>Including Author, Title, Date, Pertinent Pages, Etc.</i> )		
C62	“High Mobility Group, (HMG) Chromosomal Proteins Nomenclature Home Page” [online] [retrieved on March 9, 2006]. Retrieved from the Internet:<URL: <a href="http://www.informatics.jax.org/mgihome/nomen/genefamilies/hmgfamily.shtml">http://www.informatics.jax.org/mgihome/nomen/genefamilies/hmgfamily.shtml</a> >.	
C63	Reeves, R. and Nissen, M.S., “The A•T-DNA-binding Domain of Mammalian High Mobility Group I Chromosomal Proteins,” <i>J. Biol. Chem.</i> , 265(15):8573-8582 (1990).	
C64	Taguchi, A., <i>et al.</i> , “Blockade of RAGE-amphoterin Signalling Suppresses Tumour Growth and Metastases,” <i>Nature</i> , 405:354-360 (2000).	
C65	Taudte, S., <i>et al.</i> , “Interactions Between HMG Boxes,” <i>Protein Eng.</i> , 14(12):1015-1023 (2001).	
C66	SWISS-PROT Accession No. P09429, “High Mobility Group Protein 1 (HMG-1) (High Mobility Group Protein B1),” (2006) [online] [retrieved on 03/09/2006]. Retrieved from the Internet:<URL: <a href="http://www.ncbi.nlm.nih.gov">http://www.ncbi.nlm.nih.gov</a> >.	
C67	Yang, H., <i>et al.</i> , “HMG-1 Rediscovered as a Cytokine,” <i>Shock</i> , 15(4):247-253, (2001).	

EXAMINER	DATE CONSIDERED
----------	-----------------